Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 7OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Thymoma 1Stomach Neoplasms 1Rectal Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Fluorouracil 29Leucovorin 26Oxaliplatin 25Capecitabine 16Irinotecan 14Cetuximab 10Bevacizumab 9Radiotherapy 8Panitumumab 5Folfox protocol 5Surgical Procedures, Operative 3Levamisole 3Celecoxib 3tremelimumab 2neratinib 2napabucasin 2durvalumab 2cediranib 2aflibercept 2X-Rays 2Tegafur 2Radiofrequency Ablation 2Psychiatric Rehabilitation 2Preoperative Exercise 2Octreotide 2Mitomycin 2Interviews as Topic 2Immunoglobulin G 2Folic Acid 2Floxuridine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Colorectal Neoplasms × Ramucirumab × Clear all
NCT01079780 2023-06-28

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Eastern Cooperative Oncology Group

Phase 2 Completed
136 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡